Baxter International Stock Forecast, Price & News

Baxter International's stock was trading at $77.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BAX stock has increased by 1.5% and is now trading at $79.15.
View which stocks have been most impacted by COVID-19.

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last twelve months. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Baxter International stock.
View analyst ratings for Baxter International or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Baxter International a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Baxter International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

538 employees have rated Baxter International CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among Baxter International's employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Baxter International is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Baxter International.

Baxter International will be holding an earnings conference call on Thursday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Baxter International Inc. (NYSE:BAX) posted its earnings results on Thursday, October, 29th. The medical instruments supplier reported $0.83 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.73 by $0.10. The medical instruments supplier earned $2.97 billion during the quarter, compared to the consensus estimate of $2.84 billion. Baxter International had a return on equity of 20.81% and a net margin of 7.90%. Baxter International's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter last year, the company earned $0.74 earnings per share.
View Baxter International's earnings history.

Baxter International declared a quarterly dividend on Monday, November 16th. Shareholders of record on Friday, December 4th will be given a dividend of $0.245 per share on Monday, January 4th. This represents a $0.98 annualized dividend and a yield of 1.24%. The ex-dividend date of this dividend is Thursday, December 3rd.
View Baxter International's dividend history.

Baxter International pays an annual dividend of $0.98 per share and currently has a dividend yield of 1.24%. Baxter International has been increasing its dividend for 5 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Baxter International is 29.61%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Baxter International will have a dividend payout ratio of 28.49% next year. This indicates that Baxter International will be able to sustain or increase its dividend.
View Baxter International's dividend history.

Baxter International updated its FY 2020 IntraDay earnings guidance on Monday, January, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.673-11.673 billion, compared to the consensus revenue estimate of $11.54 billion.

17 analysts have issued 1 year price targets for Baxter International's stock. Their forecasts range from $84.00 to $105.00. On average, they anticipate Baxter International's share price to reach $94.00 in the next year. This suggests a possible upside of 18.8% from the stock's current price.
View analysts' price targets for Baxter International or view Wall Street analyst' top-rated stocks.

Baxter International saw a increase in short interest in December. As of December 31st, there was short interest totaling 6,670,000 shares, an increase of 29.0% from the December 15th total of 5,170,000 shares. Based on an average daily volume of 3,170,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.3% of the shares of the company are short sold.
View Baxter International's Short Interest.

Some companies that are related to Baxter International include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), STERIS (STE) and Varian Medical Systems (VAR).
View all of BAX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Abbott Laboratories (ABT), The Procter & Gamble (PG), AT&T (T) and Verizon Communications (VZ).

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

Baxter International's stock is owned by a number of institutional and retail investors. Top institutional investors include Bartlett & Co. LLC (0.12%), Huntington National Bank (0.11%), Beese Fulmer Investment Management Inc. (0.01%), DNB Asset Management AS (0.01%), Farmers & Merchants Investments Inc. (0.01%) and Jacobs & Co. CA (0.01%). Company insiders that own Baxter International stock include Albert P L Stroucken, Andrew Frye, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Sean Martin, Third Point Llc and Thomas T Stallkamp.
View institutional ownership trends for Baxter International.

BAX stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., NuWave Investment Management LLC, Huntington National Bank, City Holding Co., M&R Capital Management Inc., Beese Fulmer Investment Management Inc., Livingston Group Asset Management CO operating as Southport Capital Management, and Tributary Capital Management LLC. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Andrew Frye, Giuseppe Accogli, James R Gavin III, Jeanne K Mason, and John D Forsyth.
View insider buying and selling activity for Baxter International or view top insider-selling stocks.

BAX stock was acquired by a variety of institutional investors in the last quarter, including Bartlett & Co. LLC, Farmers & Merchants Investments Inc., Jacobs & Co. CA, DNB Asset Management AS, Appleton Partners Inc. MA, Park National Corp OH, Raymond James Trust N.A., and BTR Capital Management Inc..
View insider buying and selling activity for Baxter International or or view top insider-buying stocks.

Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BAX stock can currently be purchased for approximately $79.15.

Baxter International has a market capitalization of $40.43 billion and generates $11.36 billion in revenue each year. The medical instruments supplier earns $1.00 billion in net income (profit) each year or $3.31 on an earnings per share basis. Baxter International employs 50,000 workers across the globe.

The official website for Baxter International is www.baxter.com.

Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]